RxDoctor Payments Data

Stanley Dratler, MD

Family Medicine · Punta Gorda, FLNPI 1104847672

Payments from drug & device makers

$544in general payments, 2019–2025

Across 12 payments — averaging $45.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$135
  • AstraZeneca$115
  • Insulet Corporation$114
  • Dexcom, Inc.$88
  • Pfizer$79
  • Novartis$12

What the payments were for

  • Food & beverage$544100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$544 in reported general payments places this provider in the 50th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$258,422
Medicare patients
134
Services billed
2,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$85,451
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/714$24,104
XareltoRivaroxaban35$20,791
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$18,593
EntrestoSacubitril/Valsartan13$11,716
JanuviaSitagliptin Phosphate22$11,330
Fiasp FlextouchInsulin Aspart (Niacinamide)12$10,868
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$6,001
Methenamine Hippurate30$2,730
Gabapentin109$2,266
Levothyroxine Sodium207$2,167
Lacosamide13$1,822
Atorvastatin Calcium205$1,805
Metoprolol Succinate111$1,745
Rosuvastatin Calcium72$1,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$79$85,451136 claims
NovartisEntresto$12$11,71613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Punta Gorda

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →